Breast Pain & Cancer Risk

Context and Significance

Benign breast conditions, such as mastalgia (breast pain) and mastitis (breast inflammation), are extraordinarily common, compelling a significant percentage of women to seek medical evaluation during their lifetime.1 Mastalgia (breast soreness) is the single most frequent breast symptom reported in clinical settings, with estimates suggesting that 60% to 70% of women will experience it at some point.1 Similarly, mastitis (ductal infections, causing severe breast pain), while most common during lactation, represents a significant inflammatory condition of the breast. For many women presenting with these symptoms, the primary and often overwhelming concern is the fear of an underlying malignancy.1 This anxiety is a powerful driver for medical consultation and diagnostic imaging, placing a substantial burden on healthcare resources.

Framing the Problem

The relationship between these common, seemingly benign conditions and the subsequent risk of developing breast, ovarian, or uterine cancer is a subject of considerable scientific debate and clinical uncertainty. The existing body of research presents a complex and, at times, contradictory picture. Some large-scale studies conclude that breast pain alone is not a significant risk factor for cancer, while other, more specific prospective studies suggest a strong association, particularly for certain subtypes of pain. Likewise, the link between mastitis and cancer appears to diverge dramatically based on whether the inflammation is related to lactation and which type of cancer is being considered. Adding another layer of complexity are the profound physiological changes the breast undergoes during pregnancy and lactation, which can both modulate long-term cancer risk and mask the signs of a concurrent malignancy.

This report provides a comprehensive and systematic review of the qualified research literature to dissect these intricate associations. The core objective is to move beyond simplistic correlations and develop a nuanced, evidence-based understanding of risk. This requires a careful analysis of study methodologies, a critical evaluation of statistical findings, and an exploration of the biological plausibility underpinning the observed associations. By deconstructing the evidence based on the specific type of breast condition (e.g., cyclical vs. non-cyclical mastalgia; puerperal vs. non-puerperal mastitis), patient demographics, and the specific cancer outcome, this report aims to clarify the existing evidence base for clinicians, researchers, and public health analysts.

Section 1: Mastalgia and Its Association with Malignancy

The connection between mastalgia and cancer risk is one of the most debated topics in breast health, characterized by a deep divide in the scientific literature. This schism appears to stem not from flawed data, but from the heterogeneous nature of "breast pain" itself. A careful examination of the evidence reveals that the risk profile changes dramatically depending on how the symptom is defined, measured, and contextualized within a patient's broader hormonal and clinical history.

1.1. The Contested Link Between Mastalgia and Breast Cancer Risk: A Tale of Conflicting Evidence

The body of research investigating the link between mastalgia and breast cancer can be broadly categorized into two opposing camps. One argues that pain is a poor predictor of malignancy, while the other presents compelling evidence for a significant association, particularly for specific types of pain.

The "No Association" Argument

A substantial volume of evidence, particularly from large-scale studies evaluating breast pain as a general presenting symptom, concludes that mastalgia alone is not a reliable indicator of breast cancer. A landmark prospective cohort study published in the British Journal of General Practice followed 10,830 women presenting to a diagnostic clinic.5 Of the 1,972 women whose primary referral was for breast pain, the incidence of breast cancer was a mere 0.4%. This stood in stark contrast to an incidence of approximately 5% in women presenting with lumps or nipple symptoms.5 The authors of this robust study, which was noted for its prospective design and consecutive patient enrollment that minimized selection bias, went so far as to suggest that routine referral of women with only breast pain to specialist clinics is an "inefficient use of limited resources".5

This finding is echoed in other research. A retrospective study from Turkey involving 1,884 women compared a group with mastalgia to an asymptomatic control group undergoing routine screening and concluded there was no increase in the incidence of cancer in patients presenting with breast pain.6 This conclusion aligns with the general consensus communicated in numerous clinical reviews and patient-facing materials, which state that breast pain is rarely a symptom of breast cancer.4 The reported prevalence of cancer in patients whose chief complaint is mastalgia is consistently low, typically cited in the range of 0% to 7%.3 This perspective has led some to advocate for removing breast pain from public health literature as a concerning symptom associated with breast cancer.5

It is crucial to note that the duration of these studies was 12 months and 18 months, respectively, which is a relatively short period to monitor the association of hormonally driven pain with the onset of cancer.

The "Significant Association" Argument

Contradicting the above, a smaller but highly influential body of research provides strong evidence for an association, primarily when the focus is narrowed to cyclical mastalgia of significant duration and severity. The most compelling evidence comes from a French prospective cohort study of women with benign breast disease (BBD).12 In a sub-analysis of 247 women who had never used hormonal treatments, researchers found that the duration of cyclical mastalgia was a powerful and independent predictor of subsequent breast cancer risk. Over a mean follow-up of 16 years, the adjusted relative risk (RR) of breast cancer increased significantly with the duration of pain (P=0.006). For a woman experiencing cyclical mastalgia for 37 months, the RR was a striking 5.31 (95% Confidence Interval [CI], 1.92-14.72) compared to those with no such history.12

These prospective findings lend significant weight to earlier retrospective case-control studies that had pointed in the same direction. Two French case-control studies, despite the inherent limitation of potential recall bias, had previously demonstrated a significant increase in breast cancer risk related to both the duration and severity of cyclical mastalgia.12 One of these studies, involving 210 premenopausal women with breast cancer and 210 matched controls, found that a history of cyclical mastalgia was associated with more than double the risk of breast cancer (adjusted RR 2.12; 95% CI 1.31-3.43).16 Another case-control study reported that premenopausal women diagnosed with node-negative breast cancer had significantly higher premenstrual breast tenderness scores than matched controls, yielding an odds ratio (OR) of 3.32 for those with severe tenderness.3

The profound contradiction in these findings likely reflects a fundamental difference in methodology and definition. The large studies finding no association tend to group all "breast pain" together, a heterogeneous complaint that, for most women, is transient and benign. In contrast, the studies finding a strong association meticulously define and isolate cyclical mastalgia, a specific physiological marker, and track its persistence over time. This suggests that the risk is not in the symptom of pain itself, but in what a specific, persistent pattern of pain may signify about a woman's underlying hormonal environment.

Additionally, the “no association” studies had much shorter time frames for monitoring patient outcomes compared to the French study (eg, 12 or 18 months versus 16 years). To provide truly longitudinal perspectives on the risk of cancer development and onset, a longer study horizon is necessary. We would argue that an experiment design that pivots around longitudinal observational data, such as the French study, is necessary to get at the heart of this question.

Table 1: Summary of Key Studies on Mastalgia and Breast Cancer Risk

1.2. Differentiating Risk: Cyclical vs. Non-Cyclical Mastalgia

The conflicting data strongly suggest that "mastalgia" is not a single clinical entity. The distinction between cyclical and non-cyclical pain is paramount for risk assessment.

Cyclical Mastalgia is defined as bilateral, often diffuse, breast pain or tenderness that has a clear temporal relationship with the menstrual cycle.4 It typically begins during the luteal phase (one to two weeks before menses), intensifies, and then subsides with the onset of menstruation.1 This is the type of pain that is specifically implicated in the studies showing an increased risk of breast cancer.3 Its etiology is almost certainly hormonal, reflecting an end-organ response to the normal fluctuations of estrogen and progesterone.12

Non-Cyclical Mastalgia, in contrast, has no relationship to the menstrual cycle. It is more often unilateral, well-localized to a specific area, and can be constant or intermittent.4 This type of pain is more common in women in their 40s and 50s.4 While most cases of non-cyclical pain are due to benign causes like cysts, duct ectasia, or musculoskeletal issues, it carries a different, more immediate clinical concern.10 Strikingly, in the Turkish study that found no overall increase in cancer risk with mastalgia,

all five of the cancers detected within the mastalgia group occurred in women with non-cyclical pain, and four of the five were postmenopausal.6 This aligns with clinical observations that when breast cancer does present with pain, the pain is typically non-cyclical, unilateral, and well-localized.3

This distinction leads to a critical divergence in clinical thinking. Persistent, long-duration cyclical pain may not be a direct symptom of an existing tumor but rather a clinical marker of a long-term hormonal environment that is conducive to the development of hormone-sensitive cancer over many years. Conversely, new-onset, focal, non-cyclical pain, especially in a perimenopausal or postmenopausal woman, must be investigated more aggressively as it could be a rare but direct symptom of an underlying malignancy.4

1.3. Pathophysiological Hypotheses: The Hormonal Connection

The proposed link between cyclical mastalgia and breast cancer risk is rooted in endocrinology. The prevailing theory is not that hormone levels are necessarily abnormal, but that breast tissue in affected women exhibits a heightened sensitivity or an abnormal response to normal cyclical hormonal stimulation.21

The primary hypothesis centers on an imbalance between estrogen and progesterone. Evidence suggests that cyclical mastalgia may be driven by elevated estrogen levels, deficient progesterone production during the luteal phase, or an abnormal estrogen-to-progesterone ratio.3 Estrogen stimulates the proliferation of breast ductal elements, while progesterone stimulates the stroma.18 An environment of relative estrogen dominance or insufficient progesterone opposition could lead to excessive proliferation and edema that manifest as pain and swelling. This is precisely the hormonal milieu known to drive the growth of hormone receptor-positive (HR+) breast cancers, which rely on estrogen for their proliferation.22

A study of 119 women with cyclical mastalgia provided direct support for this hypothesis, finding that 63% had anovulatory cycles and 39.1% had low serum progesterone levels, indicative of insufficient progesterone action.24 This hormonal profile suggests that the breast tissue is subjected to a state of "unopposed" or inadequately opposed estrogen stimulation.

Therefore, the French cohort study authors compellingly argue that cyclical mastalgia should be viewed as an "independent and useful clinical marker of increased breast cancer risk".12 It may not be a causal factor itself, but rather a visible sign of an underlying systemic hormonal state that independently increases the long-term risk of developing a hormone-sensitive breast cancer.

1.4. Mastalgia's Relationship with Ovarian and Uterine Cancer

The available research does not establish any direct, observed link between mastalgia and the subsequent development of ovarian or uterine cancers. However, a strong connection can be inferred through shared hormonal, genetic, and iatrogenic risk factors.

Shared Hormonal Risk Factors and the Link to Uterine Cancer

The most compelling indirect link is between cyclical mastalgia and endometrial (uterine) cancer. The development of Type I endometrioid adenocarcinoma, the most common form of uterine cancer, is driven by the same mechanism hypothesized to cause cyclical mastalgia: prolonged exposure to unopposed estrogen.25 This hormonal state leads to endometrial hyperplasia, a precancerous thickening of the uterine lining.27

The Polish study that found hormonal imbalances in women with cyclical mastalgia also noted histological changes in the endometrium consistent with insufficient progesterone action.24 This provides a direct biological bridge, suggesting that cyclical mastalgia and endometrial hyperplasia may be two distinct clinical manifestations of the same underlying systemic hormonal dysfunction. A woman presenting with severe, long-duration cyclical mastalgia could, therefore, be considered to have a hormonal profile that also places her at a higher risk for endometrial pathology. This highlights the importance of a comprehensive gynecological history, including inquiry about abnormal uterine bleeding, when evaluating a patient with significant mastalgia.

Shared Genetic Risk Factors and the Link to Ovarian Cancer

The link to ovarian cancer is primarily through shared genetic predispositions. A significant portion of hereditary breast and ovarian cancers are caused by germline mutations in the BRCA1 and BRCA2 genes.22 A personal or family history of breast or ovarian cancer is a key risk factor for both diseases.19 While mastalgia itself is not a genetic marker, a patient presenting with breast pain who also has a strong family history of breast or ovarian cancer would trigger a higher level of clinical suspicion and may be a candidate for genetic counseling and testing.29

Confounding by Hormone Replacement Therapy (HRT)

Hormone replacement therapy, used to manage menopausal symptoms, further complicates the picture. HRT is a known cause of mastalgia. At the same time, it modulates the risk of gynecological cancers in complex ways. Estrogen-only HRT (ET) significantly increases the risk of uterine cancer. Conversely, combined estrogen-progestin therapy (EPT) generally protects the endometrium. However, its effect on breast cancer risk is complex and appears to depend on the specific hormones used. A large-scale meta-analysis of women under 55 found that while estrogen-only therapy was linked to a 14% reduction in breast cancer incidence, combined estrogen plus progestin therapy was associated with a 10% increase in risk compared to non-users. Other major observational studies support this increased risk with combined therapy. The Million Women Study, for instance, found that combined HRT doubled the risk of developing breast cancer compared to non-users. The French E3N cohort study further highlighted that the type of progestin is critical; it found a significantly higher risk (RR 1.69) for combinations using certain synthetic progestins compared to those using natural progesterone or dydrogesterone, which showed little to no increased risk. Both ET and EPT have been linked to a minor increase in ovarian cancer risk, especially with long-term use. Therefore, in a postmenopausal woman on HRT presenting with mastalgia, the pain is likely a side effect of the therapy, which itself is an independent and complex modulator of her cancer risk profile.

Section 2: Mastitis, Inflammation, and Cancer Risk

The association between mastitis and cancer is a tale of two distinct narratives. On one hand, a growing body of evidence links breast inflammation, particularly when it occurs outside of lactation, to an increased risk of breast cancer. This association is complicated by the fact that a rare and aggressive form of breast cancer can mimic the symptoms of mastitis, raising questions of reverse causality. On the other hand, a specific type of mastitis appears to confer a surprising and significant protective effect against ovarian cancer, mediated by the immune system.

2.1. Mastitis as a Putative Risk Factor for Breast Cancer

Multiple population-based studies have identified a history of mastitis as a significant risk factor for a subsequent breast cancer diagnosis.39 The magnitude of this risk varies across studies, likely due to differences in study populations and the types of mastitis included.

A large retrospective cohort study from Taiwan, focusing on women aged 40 and older, reported a particularly strong association. After adjusting for comorbidities, women with a history of mastitis had a 3.71 times higher risk of developing breast cancer compared to those without (adjusted Hazard Ratio 3.71; 95% CI 1.96–7.02).40 A German retrospective cohort study found a more modest but still significant overall risk, with a Hazard Ratio (HR) of 1.37 (95% CI 1.11–1.70).39 This study further stratified the risk by age, finding the association was only statistically significant in women over 50 years old (HR 1.73). A smaller Greek case-control study also supported this link, calculating a relative risk (RR) of 2.069 for breast cancer among patients with a history of mastitis.43 These consistent findings from different populations strongly suggest that an episode of mastitis is not a benign, isolated event in a woman's health history but may be a marker for future breast cancer risk.

2.2. The Critical Distinction: Puerperal vs. Non-Puerperal Mastitis

As with mastalgia, the term "mastitis" encompasses distinct clinical entities with different risk implications. The distinction between puerperal (lactational) and non-puerperal (non-lactational) mastitis is crucial.

Non-Puerperal Mastitis, which occurs unrelated to pregnancy and breastfeeding, appears to carry the more significant risk. This form of mastitis is relatively rare and is often associated with underlying conditions such as diabetes, immunosuppression, or duct ectasia.44 A Taiwanese study that specifically isolated non-lactational mastitis found an aHR of 1.94 (95% CI 1.30–2.90) for subsequent breast cancer, with the risk increasing in direct proportion to the number of episodes.41 Even more alarmingly, one prospective study reported a 37-fold increased risk of a breast cancer diagnosis within just 12 months of being treated for non-puerperal mastitis.39 While the authors acknowledged this figure might be an overestimation due to methodological bias, it underscores the potent and immediate association.

Puerperal Mastitis, which is a common complication of breastfeeding, has a much more equivocal relationship with breast cancer risk. A large Swedish cohort study found only a "slightly increased risk" associated with predominantly puerperal mastitis.39 This weak association is further complicated by the fact that breastfeeding itself is a well-established protective factor against breast cancer, particularly premenopausal and triple-negative subtypes.47 This protective effect may counterbalance or obscure any small increase in risk from the inflammatory event of mastitis. Indeed, prominent health organizations like the American Cancer Society state that having an episode of (lactational) mastitis does not increase a woman's lifetime risk for breast cancer.51

This evidence suggests that mastitis is a "two-faced" condition in oncology. A history of the condition is an incomplete data point; the critical context is whether it was related to lactation. An episode of non-puerperal mastitis, especially in an older woman, should be viewed as a significant red flag for breast cancer risk, whereas puerperal mastitis should not.

2.3. The Diagnostic Challenge: Mastitis and Inflammatory Breast Cancer (IBC)

The link between non-puerperal mastitis and breast cancer is profoundly complicated by the existence of Inflammatory Breast Cancer (IBC). IBC is a rare but highly aggressive form of the disease that does not typically present with a discrete lump. Instead, its symptoms—redness, swelling, warmth, skin thickening, and a "peau d'orange" (orange peel) texture—are virtually indistinguishable from those of mastitis.45

This symptomatic mimicry creates a dangerous potential for misdiagnosis. It is common for IBC to be initially mistaken for a simple infection and treated with a course of antibiotics.51 Because IBC can spread rapidly, this diagnostic delay can have devastating consequences for patient outcomes.45 This has led to a critical clinical guideline that emerges consistently from the research: any case of presumed mastitis, especially in a non-lactating woman, that fails to resolve completely and promptly (e.g., within one to five weeks) with appropriate antibiotic therapy must be urgently re-evaluated with a high index of suspicion for IBC.51 This re-evaluation should include imaging and, most crucially, a skin punch biopsy to look for the dermal lymphatic invasion characteristic of IBC.45

The strong, short-term association between non-puerperal mastitis and a cancer diagnosis raises a fundamental question of causality. Is the inflammation causing the cancer, or is the cancer causing the inflammation? Several experts suspect the latter, a concept known as reverse causality.46 The hypothesis is that pre-existing, non-inflammatory cancer cells block lymphatic vessels in the skin, triggering an inflammatory response that is then misdiagnosed as mastitis. The German cohort study provides strong support for this idea; it found that the statistically significant association between mastitis and breast cancer disappeared entirely when cancers diagnosed within the first two years of the mastitis episode were excluded from the analysis.39 This suggests that many cases of "mastitis" in older, non-lactating women may not be infections at all, but rather the initial presentation of an underlying malignancy.

2.4. The Mastitis-Ovarian Cancer Paradox: An Immune-Mediated Protective Effect

In a remarkable counterpoint to the breast cancer story, research has uncovered a paradoxical and protective relationship between puerperal mastitis and ovarian cancer. A large case-control study involving nearly 1,500 women with ovarian cancer and 1,600 controls found that a prior history of puerperal mastitis was associated with a significantly lower risk of developing ovarian cancer (adjusted OR 0.67; 95% CI 0.48, 0.94).57 This protective effect was dose-dependent, becoming even stronger for women who had experienced two or more episodes of mastitis (OR 0.34).

The proposed biological mechanism for this protection is entirely immune-mediated. The hypothesis is that the acute inflammation of a breast infection during the puerperium triggers a robust and long-lasting systemic immune response. This response is thought to generate antibodies against specific cell surface glycoproteins known as mucins, particularly MUC1 (also known as cancer antigen 15.3) and MUC16 (cancer antigen 125).57 These same mucins are often over-expressed by ovarian cancer cells. The theory posits that the antibodies generated during mastitis remain in circulation, creating a state of enhanced immune surveillance that can recognize and eliminate nascent ovarian cancer cells before they can establish themselves.

The study provided compelling biomarker evidence to support this hypothesis. Control subjects who reported a history of mastitis had significantly higher circulating levels of anti-MUC1 and anti-MUC16 antibodies compared to controls without such a history. Furthermore, among the women who did develop ovarian cancer, those with a prior history of mastitis had significantly lower pre-operative levels of the CA125 tumor marker.57 This suggests that the mastitis-induced antibodies may be actively binding to and clearing the tumor marker from circulation. This finding is not just a statistical curiosity; it opens a potential avenue for future research into MUC1-based vaccines to replicate this protective effect.57

2.5. Mastitis and Uterine Cancer

The provided research contains no studies that directly investigate a link between a history of mastitis and the risk of developing uterine cancer. Any connection is therefore indirect and must be inferred through the physiological context in which mastitis most often occurs.

Puerperal mastitis is, by definition, a complication of breastfeeding. Breastfeeding itself is a physiological state associated with a significantly reduced risk of endometrial (uterine) cancer.28 Meta-analyses have confirmed this protective effect, which appears to be dose-dependent, with longer durations of breastfeeding conferring greater protection.28 The mechanism is believed to be hormonal: lactation suppresses ovulation and creates a systemic hormonal environment of high progesterone and low estrogen.28 This state of progesterone dominance counteracts the proliferative effect of estrogen on the uterine lining, thereby reducing the risk of endometrial hyperplasia and cancer. Therefore, while the acute event of mastitis is inflammatory, the broader physiological state in which it most commonly arises—lactation—is protective against uterine cancer.

Table 2: Epidemiological Evidence for the Association Between Mastitis and Cancer

Section 3: Pregnancy and Reproductive History as a Modulator of Cancer Risk

Breast pain during pregnancy must be understood within the broader, well-established context of how pregnancy and reproductive history profoundly influence a woman's lifetime risk for hormone-sensitive cancers. Pregnancy is not a neutral event; it initiates a cascade of hormonal and physiological changes that have a complex, dualistic effect on cancer risk, creating a period of transiently increased vulnerability followed by long-term protection.

3.1. The Dual Effect of Pregnancy on Breast Cancer Risk

Pregnancy confers a paradoxical, time-dependent effect on breast cancer risk. In the immediate postpartum years, the risk is elevated, but over a woman's lifetime, it becomes strongly protective.59

Short-Term Increased Risk and Pregnancy-Associated Breast Cancer (PABC)

In the years immediately following childbirth, a woman's risk of developing breast cancer is transiently increased. This period of heightened risk is estimated to last for about 10 to 15 years postpartum.23 Breast cancer diagnosed during pregnancy or in the first one to five years postpartum is termed Pregnancy-Associated Breast Cancer (PABC).61

The biological rationale for this short-term risk increase is that pregnancy acts as a potent promoter of carcinogenesis. The breast undergoes rapid cell proliferation under the influence of a massive surge in hormones like estrogen, progesterone, and various growth factors.23 If a woman harbors pre-existing, dormant cells with genetic damage, this intense hormonal stimulation can accelerate their transformation into a clinically detectable tumor.59 This concept effectively frames pregnancy as a biological "stress test" for the breast; PABC is not

caused by the pregnancy but is rather unmasked or promoted by it. The risk is more pronounced in women who have their first pregnancy at a later age, as there has been more time for such random genetic mutations to accumulate in breast tissue.59 Due to diagnostic challenges, PABC often presents at a more advanced stage, with larger tumors and a higher likelihood of lymph node involvement, which can impact prognosis.59

Long-Term Protective Effect

After this transient period of increased risk, a history of full-term pregnancy provides a significant and lasting protective effect against breast cancer.23 This long-term benefit is amplified by several key reproductive factors:

• Early Age at First Full-Term Pregnancy: This is one of the most significant modulators of lifetime risk. Women who have their first full-term pregnancy before the age of 20 have approximately half the lifetime risk of developing breast cancer compared to women who delay their first birth until after age 30.22
• Parity: The protective effect is cumulative. The risk of breast cancer declines with each additional full-term pregnancy.22
• Breastfeeding: The duration of lactation provides an independent and additional risk reduction. Breastfeeding for at least a year is associated with a decreased risk of both hormone receptor-positive and -negative breast cancers.2

3.2. Breast Pain and Other Symptoms During Pregnancy: The PABC Diagnostic Challenge

During pregnancy and lactation, the breasts undergo dramatic physiological changes in preparation for nursing. They typically become larger, firmer, more nodular, and are often tender or painful.7 While these symptoms, including breast pain, are a normal part of the gestational experience, they create a significant clinical challenge by masking the potential signs of PABC.

A new lump that might be easily detected in a non-pregnant woman can be mistaken for a clogged milk duct or normal glandular tissue.69 This overlap in symptoms frequently leads to a delay in diagnosis for both the patient, who may dismiss the change as normal, and the clinician.59 Furthermore, the increased density of breast tissue during pregnancy makes mammograms more difficult to interpret and reduces their sensitivity.63

Given these challenges and the aggressive nature of PABC, the research provides clear clinical guidance: any new, persistent, and focal breast lump, localized area of pain, or skin change that develops during pregnancy or lactation should not be summarily dismissed.48 Such symptoms warrant a prompt and thorough diagnostic workup. The initial imaging modality of choice is a breast ultrasound, which is highly effective for evaluating focal abnormalities and uses no ionizing radiation, making it completely safe for the fetus.62 If ultrasound findings are suspicious or inconclusive, a mammogram can be performed safely with the use of an abdominal lead shield to protect the fetus.63 A biopsy can also be performed safely during pregnancy to obtain a definitive diagnosis.68

3.3. The Protective Effects of Childbearing and Lactation on Ovarian and Endometrial Cancers

The reproductive events of pregnancy and breastfeeding confer a powerful and consistent protective effect that extends beyond the breast to other hormone-sensitive gynecological tissues, namely the ovaries and the endometrium.

Reduced Ovarian Cancer Risk

Both having children and breastfeeding are strongly and independently associated with a reduced risk of ovarian cancer.23 A meta-analysis of 40 epidemiological studies showed that women who had ever breastfed had a 30% reduced risk of ovarian cancer compared to those who never had (pooled RR 0.70; 95% CI 0.64-0.76).72 This protection is dose-dependent; the risk continues to decrease with each additional pregnancy and with longer cumulative durations of breastfeeding.72 One study found that women who breastfed for over 13 months were 63% less likely to develop an ovarian tumor.75

The primary biological mechanism thought to underlie this protection is the "incessant ovulation" hypothesis.72 This theory posits that the repeated monthly rupture and repair of the ovarian surface during ovulation causes cumulative epithelial trauma and inflammation, which can increase the chance of malignant transformation over time. Pregnancy and lactation are periods of anovulation, effectively giving the ovaries a "rest" and reducing the total number of lifetime ovulatory cycles. This, in turn, reduces the cumulative exposure to endogenous estrogen, which can also promote the growth of ovarian tumors.72

Reduced Endometrial Cancer Risk

Similarly, a history of full-term pregnancy and lactation is protective against endometrial cancer.23 The risk declines with each additional birth.23 A meta-analysis focusing on breastfeeding found a summary RR of 0.77 for endometrial cancer in women who had breastfed, with a linear dose-response relationship showing a 2% decrease in risk for every additional month of lactation.28

The mechanism here is also hormonal but relates to the balance of estrogen and progesterone. Endometrial cancer is driven by the proliferative effects of estrogen on the uterine lining. Pregnancy and lactation are physiological states of progesterone dominance. Progesterone counteracts estrogen's effect on the endometrium, promoting differentiation rather than proliferation, and thereby reducing the risk of developing endometrial hyperplasia and cancer.28

The consistent protective effect of these reproductive events across breast, ovarian, and endometrial cancers is not coincidental. It points to a unifying biological principle: reproductive milestones that reduce a woman's cumulative lifetime exposure to ovulatory cycles and cyclical estrogen stimulation are fundamentally cancer-protective for these specific hormone-sensitive tissues.

Section 4: Synthesis, Clinical Implications, and Future Directions

The investigation into the links between common breast conditions, pregnancy, and gynecological cancers reveals a landscape of complex, interconnected risk pathways. The evidence does not support simple, linear associations but rather a nuanced model where risk is determined by the specific nature of the condition, the underlying hormonal and immune context, and a woman's reproductive history. Synthesizing these findings provides a clearer framework for clinical assessment and identifies critical areas for future research.

4.1. An Integrated Analysis of Risk Profiles

The data coalesce around four distinct but intersecting pathways that modulate cancer risk: hormonal, inflammatory, immune, and reproductive.

• The Hormonal Pathway: This is the central axis connecting cyclical mastalgia, hormone receptor-positive (HR+) breast cancer, and endometrial cancer. The underlying driver is a state of relative estrogen dominance or insufficient progesterone opposition. This hormonal milieu can manifest clinically as long-duration cyclical mastalgia, which acts as a marker of heightened breast tissue sensitivity. The same hormonal state directly promotes the proliferation of the endometrium, increasing the risk of hyperplasia and cancer. Thus, severe cyclical mastalgia and endometrial cancer can be viewed as different potential outcomes of the same systemic hormonal imbalance.
• The Inflammatory Pathway: This pathway primarily links non-puerperal mastitis to an increased risk of breast cancer. The evidence strongly suggests a relationship of reverse causality, where an underlying malignancy (particularly the aggressive IBC subtype) presents with inflammatory symptoms that mimic an infection. While chronic inflammation is a known intrinsic driver of carcinogenesis, in this specific clinical scenario, the inflammation is more likely the sign of cancer rather than its cause. This makes non-puerperal mastitis a high-risk clinical presentation demanding urgent diagnostic exclusion of malignancy.
• The Immune Pathway: This pathway explains the paradoxical protective effect of puerperal mastitis on ovarian cancer risk. In contrast to the chronic, pro-tumorigenic inflammation seen elsewhere, the acute inflammation of a lactational breast infection appears to trigger a beneficial, long-lasting systemic immune response. The generation of anti-mucin (MUC1/MUC16) antibodies creates a state of enhanced immune surveillance that is protective against ovarian cancer, highlighting the dual role of the immune system in either promoting or suppressing malignancy.
• The Reproductive Pathway: This is the most powerful and consistent modulator of long-term risk across all three cancers. Reproductive events—specifically, early age at first birth, high parity, and long duration of breastfeeding—are fundamentally protective. They achieve this by altering a woman's cumulative lifetime hormonal exposure. By reducing the total number of ovulatory cycles and shifting the systemic hormonal balance away from unopposed estrogen, these events lower the risk of breast, ovarian, and endometrial cancers through a shared, unifying biological mechanism.

Table 3: The Influence of Reproductive History on Breast, Ovarian, and Endometrial Cancer Risk

4.2. Evidence-Based Implications for Clinical Practice

The synthesis of this research provides several key takeaways for clinical practice:

• For the patient with Mastalgia: The initial step is a detailed pain history, ideally supplemented with a pain diary, to definitively classify the pain as cyclical or non-cyclical.4
• For cyclical mastalgia, reassurance is the primary intervention. Patients can be informed that the absolute risk of cancer is very low. For those with severe, persistent symptoms affecting quality of life, non-hormonal treatments (e.g., supportive bras, topical NSAIDs) should be the first line.1 The French cohort data 12, while needing confirmation, suggests that women with exceptionally long-duration cyclical pain may benefit from heightened vigilance and adherence to screening guidelines.
• For non-cyclical mastalgia, particularly if it is new-onset, focal, and occurs in a perimenopausal or postmenopausal woman, a higher index of suspicion is warranted. This presentation requires a thorough clinical examination and diagnostic imaging to rule out an underlying mass.4
• For the patient with Mastitis: The clinical approach depends entirely on the lactation status.
• For puerperal (lactational) mastitis, patients should be treated with appropriate antibiotics and supportive care and can be confidently reassured that the episode does not increase their future risk of breast cancer.51
• For non-puerperal mastitis, an aggressive approach is mandatory. The condition should be treated with antibiotics, but if symptoms and inflammatory signs do not resolve completely and rapidly, an urgent referral for imaging and skin biopsy is imperative to rule out IBC.51
• For the Pregnant or Postpartum Patient: Both patients and primary care providers must be educated that while breast tenderness and lumpiness are normal during this period, any persistent, focal, or dominant lump or skin change is abnormal and requires immediate investigation.48 Patients should be reassured about the safety of diagnostic tools like ultrasound and shielded mammography to avoid delays in diagnosis.63

4.3. Gaps in the Evidence and Recommendations for Future Research

While this review clarifies many aspects of risk, it also highlights significant gaps in the evidence that present clear directions for future research.

1. Clarifying the Mastalgia-Breast Cancer Link: The striking findings of the French cohort study on cyclical mastalgia 12 need to be replicated in larger, more diverse prospective cohorts. Future studies must use a standardized, validated definition of cyclical mastalgia and carefully control for hormonal confounders, including detailed hormonal profiling, to confirm whether it is a true independent risk marker.
2. Investigating the Mastalgia-Uterine Cancer Link: The biologically plausible but unproven link between cyclical mastalgia and endometrial cancer risk warrants investigation. A prospective study following women with severe, long-duration cyclical mastalgia and monitoring them for endometrial changes (e.g., via ultrasound and biopsy for abnormal bleeding) could establish whether mastalgia is a useful clinical marker for systemic hormonal imbalances that affect the uterus.
3. Harnessing the Immune Protection of Mastitis: The finding that puerperal mastitis is protective against ovarian cancer is one of the most intriguing in this field. Further research should focus on elucidating the precise immunological mechanisms, including the specific antigens and antibody responses involved.57 As suggested by the original researchers, this knowledge could form the basis for developing novel immunopreventive strategies, such as a MUC1-based vaccine, to mimic this natural protective effect.57
4. Improving Early Detection of PABC: Research is needed to identify biomarkers or risk stratification tools that can help identify which women are at the highest risk for developing PABC. Understanding the molecular drivers that are "unmasked" by the pregnancy stress test could lead to targeted surveillance or prevention strategies for women with known risk factors who are planning a pregnancy.

Note: if you were tracking, you might’ve noticed that none of the studies in this report cite US-based research. We included detail about country-of-origin to highlight this fact and underline the ongoing, critical need for more research into women’s health

Works cited

1. A Systematic Review of Current Understanding and Management of Mastalgia - PMC, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4141056/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC4141056/)

2. Mastalgia-Cancer Relationship: A Prospective Study - PMC, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5351493/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC5351493/)

3. Mastalgia - Breast Cancer Surgery Melbourne, VIC, accessed July 7, 2025, https://www.melbournebreastcancersurgery.com.au/wp-content/themes/ypo-theme/pdf/mastalgia-amit-goyal-and-robert-e-mansel.pdf (https://www.melbournebreastcancersurgery.com.au/wp-content/themes/ypo-theme/pdf/mastalgia-amit-goyal-and-robert-e-mansel.pdf)

4. Mastalgia - StatPearls - NCBI Bookshelf, accessed July 7, 2025, https://www.ncbi.nlm.nih.gov/books/NBK562195/ (https://www.ncbi.nlm.nih.gov/books/NBK562195/)

5. Mastalgia and breast cancer risk – GPnotebook, accessed July 7, 2025, https://gpnotebook.com/pages/oncology/mastalgia-and-breast-cancer-risk (https://gpnotebook.com/pages/oncology/mastalgia-and-breast-cancer-risk)

6. Assessment of Breast Cancer Incidence in Patients with Mastalgia and Routine Screening, accessed July 7, 2025, https://clinmedjournals.org/articles/ijsrp/international-journal-of-surgery-research-and-practice-ijsrp-6-094.php?jid=ijsrp (https://clinmedjournals.org/articles/ijsrp/international-journal-of-surgery-research-and-practice-ijsrp-6-094.php?jid=ijsrp)

7. Understanding Breast Pain | American Cancer Society, accessed July 7, 2025, https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-pain.html (https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/breast-pain.html)

8. Breast Pain (Mastalgia) | Johns Hopkins Medicine, accessed July 7, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/mastalgia-breast-pain (https://www.hopkinsmedicine.org/health/conditions-and-diseases/mastalgia-breast-pain)

9. Breast Pain: Tenderness, Causes, Diagnosis & Treatment - Cleveland Clinic, accessed July 7, 2025, https://my.clevelandclinic.org/health/diseases/15469-breast-pain-mastalgia (https://my.clevelandclinic.org/health/diseases/15469-breast-pain-mastalgia)

10. Breast pain | Canadian Cancer Society, accessed July 7, 2025, https://cancer.ca/en/cancer-information/cancer-types/breast/what-is-breast-cancer/non-cancerous-conditions/breast-pain-mastalgia (https://cancer.ca/en/cancer-information/cancer-types/breast/what-is-breast-cancer/non-cancerous-conditions/breast-pain-mastalgia)

11. Common Breast Problems | AAFP, accessed July 7, 2025, https://www.aafp.org/pubs/afp/issues/2019/0415/p505.html (https://www.aafp.org/pubs/afp/issues/2019/0415/p505.html)

12. Cyclical Mastalgia and Breast Cancer Risk: Results of A French Cohort Study, accessed July 7, 2025, https://www.researchgate.net/publication/7008875_Cyclical_Mastalgia_and_Breast_Cancer_Risk_Results_of_A_French_Cohort_Study (https://www.researchgate.net/publication/7008875_Cyclical_Mastalgia_and_Breast_Cancer_Risk_Results_of_A_French_Cohort_Study)

13. Cyclical mastalgia and breast cancer risk: results of a French cohort study - PubMed, accessed July 7, 2025, https://pubmed.ncbi.nlm.nih.gov/16775187/ (https://pubmed.ncbi.nlm.nih.gov/16775187/)

14. Cyclical Mastalgia and Breast Cancer Risk: Results of A French Cohort Study, accessed July 7, 2025, https://aacrjournals.org/cebp/article/15/6/1229/284549/Cyclical-Mastalgia-and-Breast-Cancer-Risk-Results (https://aacrjournals.org/cebp/article/15/6/1229/284549/Cyclical-Mastalgia-and-Breast-Cancer-Risk-Results)

15. Cyclical mastalgia and breast cancer risk: Results of a French cohort study, accessed July 7, 2025, https://knowledgecommons.popcouncil.org/hubs_cbr/153/ (https://knowledgecommons.popcouncil.org/hubs_cbr/153/)

16. Cyclical mastalgia as a marker of breast cancer susceptibility: results of a case-control study among French women - PubMed, accessed July 7, 2025, https://pubmed.ncbi.nlm.nih.gov/1616869/ (https://pubmed.ncbi.nlm.nih.gov/1616869/)

17. Breast pain: assessment, management, and referral criteria, accessed July 7, 2025, https://bjgp.org/content/70/697/419 (https://bjgp.org/content/70/697/419)

18. Work-up and management of breast pain - Li, accessed July 7, 2025, https://abs.amegroups.org/article/view/6968/html (https://abs.amegroups.org/article/view/6968/html)

19. Causes and Types of Mastalgia (Breast Pain) - Verywell Health, accessed July 7, 2025, https://www.verywellhealth.com/mastalgia-medical-definition-430288 (https://www.verywellhealth.com/mastalgia-medical-definition-430288)

20. Importance of mastalgia in operable breast cancer. - The BMJ, accessed July 7, 2025, https://www.bmj.com/content/284/6325/1299 (https://www.bmj.com/content/284/6325/1299)

21. Identification of Risk Factors for Mastalgia and Its Relationship with Benign or Malignant Breast Diseases - PMC, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10805056/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC10805056/)

22. Risks for breast cancer | Canadian Cancer Society, accessed July 7, 2025, https://cancer.ca/en/cancer-information/cancer-types/breast/risks (https://cancer.ca/en/cancer-information/cancer-types/breast/risks)

23. Reproductive History and Cancer Risk - NCI, accessed July 7, 2025, https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/reproductive-history-fact-sheet (https://www.cancer.gov/about-cancer/causes-prevention/risk/hormones/reproductive-history-fact-sheet)

24. [Evaluation of endometrial changes in women with cyclical mastalgia] - PubMed, accessed July 7, 2025, https://pubmed.ncbi.nlm.nih.gov/8675069/ (https://pubmed.ncbi.nlm.nih.gov/8675069/)

25. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review, accessed July 7, 2025, https://www.mdpi.com/2072-6694/12/8/2195 (https://www.mdpi.com/2072-6694/12/8/2195)

26. Risk factors for uterine cancer | Canadian Cancer Society, accessed July 7, 2025, https://cancer.ca/en/cancer-information/cancer-types/uterine/risks (https://cancer.ca/en/cancer-information/cancer-types/uterine/risks)

27. Endometrial Cancer Risk Factors, accessed July 7, 2025, https://www.cancer.org/cancer/types/endometrial-cancer/causes-risks-prevention/risk-factors.html (https://www.cancer.org/cancer/types/endometrial-cancer/causes-risks-prevention/risk-factors.html)

28. Association between Breastfeeding and Endometrial Cancer Risk: Evidence from a Systematic Review and Meta-Analysis - PubMed Central, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4517025/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC4517025/)

29. Early-Onset Breast Cancer (Breast Cancer in Young Women) - Cleveland Clinic, accessed July 7, 2025, https://my.clevelandclinic.org/health/diseases/16805-breast-cancer-in-young-women (https://my.clevelandclinic.org/health/diseases/16805-breast-cancer-in-young-women)

30. Genetics of Breast and Gynecologic Cancers (PDQ®) - NCI, accessed July 7, 2025, https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq (https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq)

31. Breast & Ovarian Cancer: Is There a Connection? - Houston Methodist, accessed July 7, 2025, https://www.houstonmethodist.org/blog/articles/2019/oct/breast-and-ovarian-cancer-is-there-a-connection/ (https://www.houstonmethodist.org/blog/articles/2019/oct/breast-and-ovarian-cancer-is-there-a-connection/)

32. Is There a Connection Between Breast Cancer & Ovarian Cancer? | Moffitt, accessed July 7, 2025, https://www.moffitt.org/cancers/ovarian-cancer/faqs/is-there-a-connection-between-breast-cancer-and-ovarian-cancer/ (https://www.moffitt.org/cancers/ovarian-cancer/faqs/is-there-a-connection-between-breast-cancer-and-ovarian-cancer/)

33. Breast cancer and ovarian cancer: The link and risk factors - Medical News Today, accessed July 7, 2025, https://www.medicalnewstoday.com/articles/breast-cancer-ovarian-cancer (https://www.medicalnewstoday.com/articles/breast-cancer-ovarian-cancer)

34. Breast and Ovarian Cancer Genetics and Prevention - Dana-Farber Cancer Institute, accessed July 7, 2025, https://www.dana-farber.org/cancer-care/treatment/cancer-genetics/syndromes-genes-programs/breast-ovarian-cancer (https://www.dana-farber.org/cancer-care/treatment/cancer-genetics/syndromes-genes-programs/breast-ovarian-cancer)

35. Menopausal Hormone Therapy and Cancer Risk | American Cancer Society, accessed July 7, 2025, https://www.cancer.org/cancer/risk-prevention/medical-treatments/menopausal-hormone-replacement-therapy-and-cancer-risk.html (https://www.cancer.org/cancer/risk-prevention/medical-treatments/menopausal-hormone-replacement-therapy-and-cancer-risk.html)

36. Current Evidence of the Oncological Benefit-Risk Profile of Hormone Replacement Therapy, accessed July 7, 2025, https://www.mdpi.com/1648-9144/55/9/573 (https://www.mdpi.com/1648-9144/55/9/573)

37. The risk of ovarian cancer in hormone replacement therapy users: a systematic review and meta-analysis - Frontiers, accessed July 7, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1414968/full (https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1414968/full)

38. Risk Factors for Ovarian Cancer: An Umbrella Review of the Literature - MDPI, accessed July 7, 2025, https://www.mdpi.com/2072-6694/14/11/2708 (https://www.mdpi.com/2072-6694/14/11/2708)

39. Is there an association between mastitis and breast cancer? a retrospective cohort study from Germany, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11564347/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC11564347/)

40. Risk of Breast Cancer in Women with Mastitis: A Retrospective Population-Based Cohort Study - PMC, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7466309/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC7466309/)

41. (PDF) Risk of breast cancer in women with non-lactational mastitis, accessed July 7, 2025, https://www.researchgate.net/publication/336906033_Risk_of_breast_cancer_in_women_with_non-lactational_mastitis (https://www.researchgate.net/publication/336906033_Risk_of_breast_cancer_in_women_with_non-lactational_mastitis)

42. (PDF) Is there an association between mastitis and breast cancer? a retrospective cohort study from Germany - ResearchGate, accessed July 7, 2025, https://www.researchgate.net/publication/383529046_Is_there_an_association_between_mastitis_and_breast_cancer_a_retrospective_cohort_study_from_Germany (https://www.researchgate.net/publication/383529046_Is_there_an_association_between_mastitis_and_breast_cancer_a_retrospective_cohort_study_from_Germany)

43. Mastitis and Risk of Breast Cancer: a Case Control-Retrospective Study and Mini-Review, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9720655/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC9720655/)

44. Mastitis: Rapid Evidence Review - BINASSS, accessed July 7, 2025, https://www.binasss.sa.cr/set24/3.pdf (https://www.binasss.sa.cr/set24/3.pdf)

45. Mastitis and Inflammatory Breast Cancer: Things You Should Know - Texas Breast Center, accessed July 7, 2025, https://www.texasbreastcenter.com/breast-cancer/mastitis-and-inflammatory-breast-cancer-things-you-should-know (https://www.texasbreastcenter.com/breast-cancer/mastitis-and-inflammatory-breast-cancer-things-you-should-know)

46. Nonpuerperal mastitis - Wikipedia, accessed July 7, 2025, https://en.wikipedia.org/wiki/Nonpuerperal_mastitis (https://en.wikipedia.org/wiki/Nonpuerperal_mastitis)

47. Reducing your risk of breast cancer, accessed July 7, 2025, https://www.cancerresearchuk.org/about-cancer/breast-cancer/risks-causes/reducing-breast-cancer-risk (https://www.cancerresearchuk.org/about-cancer/breast-cancer/risks-causes/reducing-breast-cancer-risk)

48. 6 things to know about breastfeeding and your cancer risk, accessed July 7, 2025, https://www.mdanderson.org/cancerwise/6-things-to-know-about-breastfeeding-and-your-cancer-risk.h00-159538167.html (https://www.mdanderson.org/cancerwise/6-things-to-know-about-breastfeeding-and-your-cancer-risk.h00-159538167.html)

49. ELI5: why is breastfeeding thought to lower breast cancer risk - Reddit, accessed July 7, 2025, https://www.reddit.com/r/breastfeeding/comments/1k6qka0/eli5_why_is_breastfeeding_thought_to_lower_breast/ (https://www.reddit.com/r/breastfeeding/comments/1k6qka0/eli5_why_is_breastfeeding_thought_to_lower_breast/)

50. Breast Cancer Risk Reduction | The GP Infant Feeding Network (UK), accessed July 7, 2025, https://gpifn.org.uk/breast-cancer-risk-reduction/ (https://gpifn.org.uk/breast-cancer-risk-reduction/)

51. Breast Mastitis | Mastitis Causes, Symptoms, and Treatment | American Cancer Society, accessed July 7, 2025, https://www.cancer.org/cancer/types/breast-cancer/non-cancerous-breast-conditions/mastitis.html (https://www.cancer.org/cancer/types/breast-cancer/non-cancerous-breast-conditions/mastitis.html)

52. Inflammatory Breast Cancer vs. Mastitis: How to Differentiate Between the Two, accessed July 7, 2025, https://www.americanoncology.com/blogs/inflammatory-breast-cancer-vs-mastitis-how-to-differentiate-between-the-two (https://www.americanoncology.com/blogs/inflammatory-breast-cancer-vs-mastitis-how-to-differentiate-between-the-two)

53. Inflammatory breast cancer - Symptoms and causes - Mayo Clinic, accessed July 7, 2025, https://www.mayoclinic.org/diseases-conditions/inflammatory-breast-cancer/symptoms-causes/syc-20355413 (https://www.mayoclinic.org/diseases-conditions/inflammatory-breast-cancer/symptoms-causes/syc-20355413)

54. Mastitis or breast cancer? Know the difference, accessed July 7, 2025, https://www.roswellpark.org/cancertalk/202303/mastitis-or-breast-cancer-know-difference (https://www.roswellpark.org/cancertalk/202303/mastitis-or-breast-cancer-know-difference)

55. Mastitis and Breast Cancer - News-Medical.net, accessed July 7, 2025, https://www.news-medical.net/health/Mastitis-and-Breast-Cancer.aspx (https://www.news-medical.net/health/Mastitis-and-Breast-Cancer.aspx)

56. Non-puerperal mastitis masking pre-existing breast malignancy: importance of follow-up imaging - PubMed Central, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4825209/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC4825209/)

57. Puerperal Mastitis: a Reproductive Event of Importance Affecting Anti-Mucin Antibody Levels and Ovarian Cancer Risk, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3805704/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC3805704/)

58. Breastfeeding and the incidence of endometrial cancer: A meta-analysis | Oncotarget, accessed July 7, 2025, https://www.oncotarget.com/article/5049/text/ (https://www.oncotarget.com/article/5049/text/)

59. Pregnancy Confers 'Dual Effect' on Breast Cancer Risk - The ASCO Post, accessed July 7, 2025, https://ascopost.com/issues/december-10-2022/pregnancy-confers-dual-effect-on-breast-cancer-risk/ (https://ascopost.com/issues/december-10-2022/pregnancy-confers-dual-effect-on-breast-cancer-risk/)

60. Breast Cancer Risk: Age at First Childbirth | Susan G. Komen®, accessed July 7, 2025, https://www.komen.org/breast-cancer/risk-factor/age-at-first-childbirth/ (https://www.komen.org/breast-cancer/risk-factor/age-at-first-childbirth/)

61. Risk Factors for Pregnancy-Associated Breast Cancer: A Report from the Nigerian Breast Cancer Study, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3770152/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC3770152/)

62. Pregnancy-Associated Breast Cancer: Key Concepts for Optimizing Diagnosis and Treatment | JCO Oncology Practice - ASCO Publications, accessed July 7, 2025, https://ascopubs.org/doi/10.1200/OP-24-00867 (https://ascopubs.org/doi/10.1200/OP-24-00867)

63. Pregnancy Associated Breast Cancer - Journal of Clinical Imaging Science, accessed July 7, 2025, https://clinicalimagingscience.org/pregnancy-associated-breast-cancer/ (https://clinicalimagingscience.org/pregnancy-associated-breast-cancer/)

64. Pregnancy-Associated Breast Cancer: A Diagnostic and Therapeutic Challenge - PMC, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9955856/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC9955856/)

65. Impact of Pregnancy on Breast Cancer Features and Prognosis - MDPI, accessed July 7, 2025, https://www.mdpi.com/1718-7729/31/4/171 (https://www.mdpi.com/1718-7729/31/4/171)

66. The Impact of Pregnancy on Breast Cancer Outcomes in Women ≤35 Years - PMC, accessed July 7, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3063387/ (https://pmc.ncbi.nlm.nih.gov/articles/PMC3063387/)

67. Breast cancer during pregnancy: Treatments, safety, and more - Medical News Today, accessed July 7, 2025, https://www.medicalnewstoday.com/articles/breast-cancer-in-pregnancy (https://www.medicalnewstoday.com/articles/breast-cancer-in-pregnancy)

68. Finding Breast Cancer During Pregnancy, accessed July 7, 2025, https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/finding-breast-cancer-during-pregnancy.html (https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/finding-breast-cancer-during-pregnancy.html)

69. Breast Cancer During Pregnancy - Tampa General Hospital, accessed July 7, 2025, https://www.tgh.org/institutes-and-services/conditions/breast-cancer-during-pregnancy (https://www.tgh.org/institutes-and-services/conditions/breast-cancer-during-pregnancy)

70. Breast cancer during pregnancy | Cancer Research UK, accessed July 7, 2025, https://www.cancerresearchuk.org/about-cancer/breast-cancer/living-with/breast-cancer-during-pregnancy (https://www.cancerresearchuk.org/about-cancer/breast-cancer/living-with/breast-cancer-during-pregnancy)

71. Breast Imaging and Intervention during Pregnancy and Lactation - RSNA Journals, accessed July 7, 2025, https://pubs.rsna.org/doi/full/10.1148/rg.230014 (https://pubs.rsna.org/doi/full/10.1148/rg.230014)

72. Breastfeeding and Ovarian Cancer Risk: a Systematic Review and Meta-analysis of 40 Epidemiological Studies - ResearchGate, accessed July 7, 2025, https://www.researchgate.net/publication/263746012_Breastfeeding_and_Ovarian_Cancer_Risk_a_Systematic_Review_and_Meta-analysis_of_40_Epidemiological_Studies (https://www.researchgate.net/publication/263746012_Breastfeeding_and_Ovarian_Cancer_Risk_a_Systematic_Review_and_Meta-analysis_of_40_Epidemiological_Studies)

73. The Effect of Breastfeeding Duration and Parity on the Risk of Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis - Journal of Preventive Medicine and Public Health, accessed July 7, 2025, https://www.jpmph.org/journal/view.php?number=1889 (https://www.jpmph.org/journal/view.php?number=1889)

74. Breastfeeding and ovarian cancer risk: a systematic review and meta-analysis of 40 epidemiological studies - PubMed, accessed July 7, 2025, https://pubmed.ncbi.nlm.nih.gov/24998548/ (https://pubmed.ncbi.nlm.nih.gov/24998548/)

75. Extended Breastfeeding Reduces the Risk of Ovarian Cancer, accessed July 7, 2025, https://ocrahope.org/news/extended-breastfeeding-reduces-the-risk-of-ovarian-cancer/ (https://ocrahope.org/news/extended-breastfeeding-reduces-the-risk-of-ovarian-cancer/)